Lecarpentier, JulieSilvestri, ValentinaKuchenbaecker, Karoline BBarrowdale, DanielDennis, JoeMcGuffog, LesleySoucy, PennyLeslie, GoskaRizzolo, PieraNavazio, Anna SaraValentini, VirginiaZelli, VeronicaLee, AndrewAmin Al Olama, AliTyrer, Jonathan PSouthey, MelissaJohn, Esther MConner, Thomas AGoldgar, David EBuys, Saundra SJanavicius, RamunasSteele, LindaDing, Yuan ChunNeuhausen, Susan LHansen, Thomas V OOsorio, AnaWeitzel, Jeffrey NToss, AngelaMedici, VeronicaCortesi, LauraZanna, InesPalli, DomenicoRadice, PaoloManoukian, SiranoushPeissel, BernardAzzollini, JacopoViel, AlessandraCini, GiuliaDamante, GiuseppeTommasi, StefaniaPeterlongo, PaoloFostira, FlorentiaHamann, UteEvans, D GarethHenderson, AlexBrewer, CaroleEccles, DianaCook, JackieOng, Kai-RenWalker, LisaSide, Lucy EPorteous, Mary EDavidson, RosemarieHodgson, ShirleyFrost, DebraAdlard, JulianIzatt, LouiseEeles, RosEllis, SteveTischkowitz, MarcGodwin, Andrew KMeindl, AlfonsGehrig, AndreaDworniczak, BerndSutter, ChristianEngel, ChristophNiederacher, DieterSteinemann, DorisHahnen, EricHauke, JanRhiem, KerstinKast, KarinArnold, NorbertDitsch, NinaWang-Gohrke, ShanWappenschmidt, BarbaraWand, DorotheaLasset, ChristineStoppa-Lyonnet, DominiqueBelotti, MurielDamiola, FrancescaBarjhoux, LaureMazoyer, SylvieVan Heetvelde, MattiasPoppe, BruceDe Leeneer, KimClaes, Kathleen B Mde la Hoya, MiguelGarcia-Barberan, VanesaCaldes, TrinidadPerez Segura, PedroKiiski, Johanna IAittomäki, KristiinaKhan, SofiaNevanlinna, Helivan Asperen, Christi JVaszko, TiborKasler, MiklosOlah, EdithBalmaña, JudithGutiérrez-Enríquez, SaraDiez, OrlandTeulé, AlexIzquierdo, AngelDarder, EstherBrunet, JoanDel Valle, JesúsFeliubadalo, LidiaPujana, Miquel AngelLazaro, ConxiArason, AdalgeirAgnarsson, Bjarni AJohannsson, Oskar ThBarkardottir, Rosa BAlducci, ElisaTognazzo, SilviaMontagna, MarcoTeixeira, Manuel RPinto, PedroSpurdle, Amanda BHolland, HeleneLee, Jong WonLee, Min HyukLee, JihyounKim, Sung-WonKang, EunyoungKim, ZisunSharma, PriyankaRebbeck, Timothy RVijai, JosephRobson, MarkLincoln, AnneMusinsky, JacobGaddam, PragnaTan, Yen YBerger, AndreasSinger, Christian FLoud, Jennifer TGreene, Mark HMulligan, Anna MarieGlendon, GordAndrulis, Irene LToland, Amanda EwartSenter, LeighaBojesen, AndersNielsen, Henriette RoedSkytte, Anne-BineSunde, LoneJensen, Uffe BirkPedersen, Inge SokildeKrogh, LotteKruse, Torben ACaligo, Maria AYoon, Sook-YeeTeo, Soo-Hwangvon Wachenfeldt, AnnaHuo, DezhengNielsen, Sarah MOlopade, Olufunmilayo INathanson, Katherine LDomchek, Susan MLorenchick, ChristaJankowitz, Rachel CCampbell, IanJames, PaulMitchell, GillianOrr, NickPark, Sue KyungThomassen, MadsOffit, KennethCouch, Fergus JSimard, JacquesEaston, Douglas FChenevix-Trench, GeorgiaSchmutzler, Rita KAntoniou, Antonis COttini, Laura2019-09-272019-09-272017-07-10J Clin Oncol. 2017;35(20):2240-22500732-183Xhttp://hdl.handle.net/20.500.12105/8384Purpose BRCA1/2 mutations increase the risk of breast and prostate cancer in men. Common genetic variants modify cancer risks for female carriers of BRCA1/2 mutations. We investigated-for the first time to our knowledge-associations of common genetic variants with breast and prostate cancer risks for male carriers of BRCA1/ 2 mutations and implications for cancer risk prediction. Materials and Methods We genotyped 1,802 male carriers of BRCA1/2 mutations from the Consortium of Investigators of Modifiers of BRCA1/2 by using the custom Illumina OncoArray. We investigated the combined effects of established breast and prostate cancer susceptibility variants on cancer risks for male carriers of BRCA1/2 mutations by constructing weighted polygenic risk scores (PRSs) using published effect estimates as weights. Results In male carriers of BRCA1/2 mutations, PRS that was based on 88 female breast cancer susceptibility variants was associated with breast cancer risk (odds ratio per standard deviation of PRS, 1.36; 95% CI, 1.19 to 1.56; P = 8.6 × 10-6). Similarly, PRS that was based on 103 prostate cancer susceptibility variants was associated with prostate cancer risk (odds ratio per SD of PRS, 1.56; 95% CI, 1.35 to 1.81; P = 3.2 × 10-9). Large differences in absolute cancer risks were observed at the extremes of the PRS distribution. For example, prostate cancer risk by age 80 years at the 5th and 95th percentiles of the PRS varies from 7% to 26% for carriers of BRCA1 mutations and from 19% to 61% for carriers of BRCA2 mutations, respectively. Conclusion PRSs may provide informative cancer risk stratification for male carriers of BRCA1/2 mutations that might enable these men and their physicians to make informed decisions on the type and timing of breast and prostate cancer risk management.engVoRhttp://creativecommons.org/licenses/by-nc-sa/4.0/AdultAge FactorsAgedAtribución-NoComercial-CompartirIgual 4.0 Internacional2844824135202240-225010.1200/JCO.2016.69.49351527-7755Journal of clinical oncology : official journal of the American Society of Clinical Oncologyopen access